Semin Thromb Hemost 2006; 32(3): 208-218
DOI: 10.1055/s-2006-939432
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Budd-Chiari Syndrome and Portal Vein Thrombosis Associated with Myeloproliferative Disorders: Diagnosis and Management

Jean B. Brière1
  • 1Hematology Unit Beaujon Hospital, Clichy, France
Further Information

Publication History

Publication Date:
02 May 2006 (online)

ABSTRACT

The improvement observed in the prognosis of Budd-Chiari syndrome (BCS) since 1985 may be related to a better identification of underlying prothrombotic states. In a recent investigation of the currently identified prothrombotic disorders, one or several prothrombotic disorders were evidenced in 72% of patients with portal vein thrombosis (PVT) and 87% of patients with hepatic vein thrombosis. According to the different criteria used for their diagnosis, myeloproliferative disorders (MPDs) were reported in 25 to 65% of patients with splanchnic vein thrombosis (STV). In a single-center retrospective study of 128 patients with STV, clusters of abnormal megakaryocytes in bone marrow biopsy combined with endogenous erythrocyte colony formation were used as reference standards for a diagnosis of MPD. These two criteria allowed the diagnosis of MPDs at risk of aggravation in 25% (26 of 103) of patients with STV (41% in BCS; 23% in PVT). After a mean follow-up of 6.09 ± 6.6 years, hematologic progression was confirmed in 23% of patients with the two criteria both positive, whereas neither progression nor features suggestive of MPD were observed in patients with the same concordant negative criteria. The combination of marked splenomegaly and platelet count > 200 × 109/L that was never observed in patients without MPD, constitutes a simple index for the suspicion of an underlying MPD, but the absence of an obvious splenic enlargement and normal or decreased platelet numbers may even be observed in patients with MPD-associated STV. In the absence of reliable indicators of the exact expansion of the myeloproliferative clone, the therapeutic management of STV-associated MPD is difficult to standardize. Owing to the suspected incidence on the prognosis of BCS of an associated MPD, the present watchful-waiting attitude proposed in MPD without obvious hematologic expression may be challenged.

REFERENCES

  • 1 Anger B R, Seifried E, Scheppach J, Heimpel H. Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases.  Klin Wochenschr. 1989;  67 818-825
  • 2 Valla D C. Hepatic vein thrombosis (Budd-Chiari syndrome).  Semin Liver Dis. 2002;  22 5-14
  • 3 De Stefano V, Teofili L, Leone G, Michiels J J. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis.  Semin Thromb Hemost. 1997;  23 411-418
  • 4 Valla D, Casadevall N, Lacombe C et al.. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari Syndrome.  Ann Intern Med. 1985;  103 329-334
  • 5 Temerinac S, Klippel S, Strunk E et al.. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia vera.  Blood. 2000;  95 2569-2576
  • 6 James C, Ugo V, Le Couedic J P et al.. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.  Nature. 2005;  434 1144-1148
  • 7 Georgii A, Burh T, Buesche G, Kreft A, Choritz H. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies.  Leuk Lymphoma. 1996;  22 15-19
  • 8 Thiele J, Kvasnicka H M. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients.  Ann Hematol. 2003;  82 148-152
  • 9 Chait Y, Condat B, Cazals-Hatem D et al.. Relevance of the criteria commonly used to diagnose myeloproliferative disorders in patients with splanchnic vein thrombosis.  Br J Haematol. 2005;  129 553-560
  • 10 Janssen H L, Garcia-Pagan J C, Elias E, Mentha G, Hadengue A, Valla D C. European Group for the Study of Vascular Disorders of the Liver . Budd-Chiari syndrome: a review by an expert panel.  J Hepatol. 2003;  38 364-371
  • 11 Okuda K. Inferior vena cava thrombosis at its hepatic portion (obliterative hepatocavopathy).  Semin Liver Dis. 2002;  22 15-26
  • 12 Sarin S K, Agarwal S R. Extrahepatic portal vein obstruction.  Semin Liver Dis. 2002;  22 43-58
  • 13 Condat B, Pessione F, Hillaire S et al.. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy.  Gastroenterology. 2001;  120 490-497
  • 14 Denninger M H, Chait Y, Casadevall N et al.. Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors.  Hepatology. 2000;  31 587-591
  • 15 Valla D, Le M G, Poynard T et al.. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptive. A case-control study.  Gastroenterology. 1986;  90 807-811
  • 16 Dilawari J B, Bambery P, Chawla Y et al.. Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature.  Medicine (Baltimore). 1994;  73 21-36
  • 17 Wanless I R, Peterson P, Das A et al.. Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: a clinicopathological study of 145 patients examined at autopsy.  Hepatology. 1990;  12 1166-1174
  • 18 Pearson T C, Guthrie D L, Simpson J et al.. Interpretation of measured red cell mass and plasma volume in the adults: expert panel on radionuclides of the International Council for Standardization in Haematology.  Br J Haematol. 1995;  89 748-756
  • 19 Birgegard G, Wide L. Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment.  Br J Haematol. 1992;  81 603-606
  • 20 Messinezy M, Westwood N B, El-Hemaidi I et al.. Serum erythropoietin values in erythroses and in primary thrombocythaemia.  Br J Haematol. 2002;  117 47-53
  • 21 Westwood N B, Pearson T C. Diagnostic implications of haematopoietic progenitor culture techniques in polycythaemia and thrombocytaemia.  Leuk Lymphoma. 1996;  22 95-103
  • 22 Imbert M, Pierre R, Thiele J et al.. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Essential thrombocythemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW World Health Organization Classification of Tumours. Lyon, France; IARC Press 2001: 39-41
  • 23 Thiele J, Pierre R, Imbert M et al.. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW World Health Organization Classification of Tumours. Lyon, France; IARC Press 2001: 35-38
  • 24 Reid C D, Chanarin I, Lewis J. Formes frustes in myeloproliferative disorders. Identification by the growth of an endogenous erythroid clone in vitro in patients with arterial vascular disease.  Lancet. 1982;  1 14-16
  • 25 Dainiak N, Hoffman R, Lebowitz A, Solomon M, Maffei L, Ritchey K. Erythropoietin-dependent primary pure erythrocytosis.  Blood. 1979;  53 1076-1084
  • 26 Eridani S, Pearson T C, Sawyer B, Batten E, Wetherley-Mein G. Erythroid colony formation in primary proliferative polycythaemia, idiopathic erythrocytosis and secondary polycythemia: sensitivity to erythropoietic stimulating factors.  Clin Lab Haematol. 1983;  5 121-129
  • 27 Eridani S, Sawyer B, Pearson T C. Patterns of in vitro BFU-E proliferation in different forms of polycythaemia and thrombocythaemia.  Eur J Haematol. 1987;  38 363-369
  • 28 Spivac J L. Polycythemia vera: myths, mechanisms, and management.  Blood. 2002;  100 4272-4290
  • 29 Thiele J, Kvasnicka H M, Diehl V, Fischer R, Michiels J J. Clinicopathological diagnosis and differential criteria of thrombocythemia in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies.  Leuk Lymphoma. 1999;  33 207-218
  • 30 Lengfelder E, Hochhaus A, Kronawitter U et al.. Should a platelet limit of 600 × 109/L be used as a diagnostic criterion in essential thrombocythemia? An analysis of the natural course including early stages.  Br J Haematol. 1998;  100 15-23
  • 31 Sacchi S, Vinci G, Gugliotta L et al.. Diagnosis of essential thrombocythemia at platelet counts between 400 and 600 × 109/l.  Haematologica. 2000;  85 492-495
  • 32 Klippel S, Stunk E, Busse C E, Behringer D, Pahl H L. Biochemical characterization of PRV-1, a novel hematopoietic cell surface receptor, which is overexpressed in polycythemia rubra vera.  Blood. 2002;  100 2441-2448
  • 33 Griesshammer M, Klippel S, Strunck E et al.. PRV-1 mRNA expression discriminates two types of essential thrombocythemia.  Ann Hematol. 2004;  83 364-370
  • 34 Kralovics R, Passamonti F, Buser A S et al.. A gain of function mutation of JAK2 in myeloproliferative disorders.  N Engl J Med. 2005;  352 1779-1790
  • 35 Baxter E J, Scott L M, Campbell P J et al.. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.  Lancet. 2005;  365 1054-1061
  • 36 Levine R L, Wadleigh M, Cools J et al.. Activating mutation in the tyrosine kinase JAK2 in polycythemia, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.  Cancer Cell. 2005;  7 387-397
  • 37 Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense.  Blood. 2005;  105 4187-4190
  • 38 Zeitoun G, Escolano S, Hadengue A et al.. Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting.  Hepatology. 1999;  30 84-89
  • 39 Melear J M, Goldstein R M, Levy M F et al.. Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders.  Transplantation. 2002;  74 1090-1095
  • 40 Radin A I, Kim H T, Grant B W et al.. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.  Cancer. 2003;  98 100-109
  • 41 Alvarado Y, Cortes J, Verstovsek S et al.. Pilot study of pegylated interferon alpha eb in patients with essential thrombocythemia.  Cancer Chemother Pharmacol. 2003;  51 81-86
  • 42 Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases.  Br J Haematol. 2005;  129 293-306
  • 43 Harrison C, Campbell P J, Buck G et al.. Hydroxyurea compared to anagrelide in high-risk essential thrombocythemia.  N Engl J Med. 2005;  353 33-45

Jean B BrièreM.D. 

Professor, Hematology Unit Beaujon Hospital

100Bd Gėnėral Leclerc, 92118 Clichy, France

Email: jean.briere@bjn.ap-hop-paris.fr

    >